摘要
目的:探究表柔比星联合新辅助化疗治疗三阴性乳腺癌的最佳剂量.方法:选取本院2014年8月—2015年5月收治的三阴性乳腺癌患者72例,按随机数字表法分为对照组和试验组,各36例.试验组给予表柔比星(90 mg/m2,静脉滴注)联合新辅助化疗治疗,对照组给予表柔比星(70 mg/m2,静脉滴注)联合新辅助化疗治疗.比较两组临床疗效、毒副反应发生情况、肿瘤患者一般状况评分(Kamofsky评分)以及总生存率.结果:试验组总有效率高于对照组,差异有统计学意义(P<0.05);试验组Kamofsky评分高于对照组,差异有统计学意义(P<0.05);两组毒副反应情况、治疗后1年、2年、3年生存率比较,差异无统计学意义(P>0.05).结论:90 mg/m2表柔比星联合新辅助化疗治疗三阴性乳腺癌临床疗效更显著,在毒副反应可耐受的情况下,可提高患者的生活质量,值得临床推广使用.
Objective:To explore the optimal dose of epirubicin combined with neoadjuvant chemotherapy for triple-negative breast cancer.Methods:72 patients with triple-negative breast cancer admitted to our hospital from August 2014 to May 2015 were selected and randomly divided into a control group and an experimental group,36 cases each.The patients in the experimental group were given epirubicin(90 mg/m2,intravenous drip)combined with neoadjuvant chemotherapy,and the patients in the control group were given epirubicin(70 mg/m2,intravenous drip)combined with neoadjuvant chemotherapy.The clinical efficacy,the incidence of toxicity and other side effects,the scores of the general status of the tumor patients(Kamofsky scores)and the overall survival rate were compared between the two groups.Results:The total effective rate in the experimental group was higher than that in the control group,and the difference was statistically significant(P<0.05).The Kamofsky scores in the experimental group were higher than those in the control group,and the difference was statistically significant(P<0.05).There was no statistically significant difference in the incidence of toxicity and other side effects after 1 year,2 years,and 3 years of treatment(P<0.05).Conclusion:90 mg/m2 epirubicin combined with neoadjuvant chemotherapy has more significant clinical efficacy in the treatment of triple-negative breast cancer,which can improve the quality of life of the patients in the case of tolerable toxicity and other side effects,and is worthy of clinical popularization and application.
作者
王西礼
Wang Xi-li(Department of Mammary gland and Thyroid,Kaifeng Central Hospital,Kaifeng Henan 475000,China)
出处
《中国合理用药探索》
CAS
2019年第6期146-149,共4页
Chinese Journal of Rational Drug Use
关键词
表柔比星
剂量讨论
三阴性乳腺癌
新辅助化疗
Epirubicin
Dose Discussion
Triple Negative Breast Cancer
Neoadjuvant Chemotherapy
